Cell Cycle
The cell cycle consists of a regulatory network of proteins that controls the order and timing of cellular proliferation events. It is divided into four stages, G1-S-G2-M. The G1 and G2 stages stands for 'GAP 1' and 'GAP 2' respectively. The S stage stands for 'Synthesis' and is the stage when DNA replication occurs. The M stage stands for 'mitosis', and is when nuclear and cytoplasmic division occurs, halving the genome.
Cell Cycle Products Targets
Products for Cell Cycle - Page 7
- Cat.No. Product Name Information/Activity
-
BCC1034
Dynamin inhibitory peptide
Dynamin inhibitor
-
BCC1088
Dynasore
Dynasore is a cell-permeable dynamin inhibitor with an IC50 of 15 μM.
-
BCC7298
Flutax 1
191930-58-2
-
BCC1614
GW843682X
GW843682X is a selective, ATP-competitive inhibitor of PLK1 and PLK3, with IC50s of 2.2 nM and 9.1 nM, respectively, and is also >100-fold selective against ∼30 other kinases.
-
BCC6040
INH1
INH1 is a small molecule targeting the Hec1/Nek2 mitotic pathway suppresses tumor cell growth in culture and in animal.
-
BCC2402
Mdivi 1
Mdivi-1 is a selective dynamin-related protein 1 (Drp1) inhibitor. Mdivi-1 is a mitochondrial division/mitophagy inhibitor.
-
BCC1775
Monomethyl auristatin E
Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types.
-
BCC3826
Nocodazole
Nocodazole is a rapidly-reversible inhibitor of microtubule. Nocodazole binds to β-tubulin and disrupts microtubule assembly/disassembly dynamics, which prevents mitosis and induces apoptosis in tumor cells. Nocodazole inhibits Bcr-Abl, and activates CRISPR/Cas9.
-
BCC3819
Noscapine HCl
Bradykinin antagonist. Also tubulin inhibitor
-
BCC6408
SBE 13 HCl
SBE13 Hydrochloride is a potent and selective Plk1 inhibitor, with an IC50 of 200 pM; SBE13 Hydrochloride poorly inhibits Plk2 (IC50>66 μM) or Plk3 (IC50=875 nM).


